| Patent Number |
Title Of Patent |
Date Issued |
| 7442687 |
2-polycyclic propynyl adenosine analogs having A2A agonist activity |
October 28, 2008 |
| The invention provides compounds having the following general formula (I): ##STR00001## wherein X, R.sup.1, R.sup.2, R.sup.7 and Z are as described herein. |
| 6660276 |
Peptides recognized by melanoma-specific cytotoxic lymphocytes, and uses therefor |
December 9, 2003 |
| The instant disclosure identifies and synthesizes peptide residues initially isolated from a melanoma cell line. The peptides are capable of reconstituting an epitope recognized by tumor specific CTL. Some of the sequences are homologous with proteins identified as pMEL17, tyrosinase |
| 6617355 |
Treating asthma by preventing and/or accomodating S-nitrosothiol breakdown |
September 9, 2003 |
| Asthma is ameliorated, and mild or moderate asthma is prevented from progressing to more severe asthma by administering agents which prevent and/or accommodate for S-nitrosothiol breakdown. |
| 6596534 |
Utilization of osteocalcin promoter to deliver therapeutic genes to tumors |
July 22, 2003 |
| A therapeutic agent based on a recombinant adenovirus which employs an osteocalcin promoter for the expression of thymidine kinase can be administered intravascularly to treat metastatic cancer, including osteosarcoma, breast cancer, prostate cancer, ocular melanoma or brain cancer. |
| 6572856 |
Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies |
June 3, 2003 |
| The present invention relates to the treatment and prevention of cancer, viral infections and microbial infections by the administration of anti-C3b(i) antibodies. The present invention also relates to methods of treating and preventing cancer, viral infection, or microbial infection in |
| 6558671 |
Cysteine-depleted peptides recognized by A3-restricted cytotoxic lymphocytes, and uses therefor |
May 6, 2003 |
| Cysteine-depleted CTL epitopes can elicit a stronger or more specific CTL response than the native, cysteine-containing CTL epitope of a disease associated antigen. |
| 6330469 |
Method and apparatus for the early diagnosis of subacute, potentially catastrophic illness |
December 11, 2001 |
| In one aspect of the invention, there is provided a method and apparatus for early detection of subacute, potentially catastrophic infectious illness in a premature newborn infant. The method comprises: (a) continuously monitoring heart rate variability in the premature newborn infan |
| 6216032 |
Method and apparatus for the early diagnosis of subacute, potentially catastrophic illness |
April 10, 2001 |
| In one aspect, there is provided a method and apparatus for early detection of subacute, potentially catastrophic infectious illness in a premature newborn infant. The method comprises: (a) continuously monitoring heart rate variability in the premature newborn infant; and (b) identifyin |
| 6192320 |
Interactive remote sample analysis system |
February 20, 2001 |
| An interactive multi-station medical specimen analysis system for simultaneously analyzing a medical specimen at remote locations and accessing, for evaluation, the results of each of the analyses at a central laboratory is disclosed. A central laboratory, interacts with remote compu |
| 6180612 |
Methods and compositions for targeting DNA metabolic processes using aminoglycoside derivatives |
January 30, 2001 |
| Protein targets for disease intervention through inhibition of nucleic acid metabolism are disclosed. Novel polypeptides for one such target, DNA-dependent ATPase A, and novel polynucleotides encoding DNA-dependent ATPase A are disclosed. Phosphoaminoglycoside compounds which act on such |
| 6159467 |
In vivo suppression of osteosarcoma pulmonary metastasis with intravenous osteocalcin promoter-b |
December 12, 2000 |
| A therapeutic agent based on a recombinant adenovirus which employs an osteocalcin promoter for the expression of thymidine kinase can be administered intravascularly to treat metastatic cancer, including osteosarcoma, breast cancer, prostate cancer, ocular melanoma or brain cancer. |
| 6096021 |
Flow arrest, double balloon technique for occluding aneurysms or blood vessels |
August 1, 2000 |
| A method for occluding aneurysms or peripheral blood vessels is provided which allows for isovolumetric, isobaric delivery of occluding agents to aneurysms or peripheral blood vessels, wherein the aneurysms or peripheral blood vessels are isolated from the general circulation until the |
| 6093697 |
Synthetic insulin mimetic substances |
July 25, 2000 |
| Compounds are disclosed which have the formula (I) ##STR1## wherein R.sub.1 -R.sub.2 are each independently selected from the group consisting of: (a) a hydrogen atom; and (b) a lower alkyl group, straight or branched chain, having 1 to 8 carbon atoms; or R.sub.1 -R.sub.2 and the |
| 6075057 |
Inhibition of carbohydrates metabolism by quinone compounds |
June 13, 2000 |
| Optically pure enantiomers of avarol are obtained. The enantiomers of avarol are demonstrated to be highly effective inhibitors of .alpha.-glucosidase and .alpha.-mannosidase. Other enzymes assayed were not inhibited by these optically pure compounds. Inhibition of these two enzymes |
| 6004986 |
Method for treating cerebral vasospasm and cerebral ischemia using iron chelators and pharmaceut |
December 21, 1999 |
| The invention relates to methods for treating cerebral vasospasm induced by hemorrhage or cerebral ischemia, by treating patients with a therapeutically effective amount of a lipophilic iron chelator. |
| 5986275 |
Reusable shielded marker for nuclear medicine imaging |
November 16, 1999 |
| A reusable shielded marker for nuclear medicine imaging provides a chamber of radiation-shielding material such as lead to receive the radiodnuclide such as technetium pertechnetate. The chamber is mounted on a spring which also bears a shutter provided with an aperture. When force is ap |
| 5973114 |
Isolation and characterization of the growth hormone releasing hormone receptor |
October 26, 1999 |
| Growth hormone releasing hormone (GHRH) receptor binding has been characterized using a unique binding assay utilizing iodinated GHRH probes. Photoaffinity GHRH probes have been constructed which allow for photolabeling and characterization of the receptor. In addition, high affinity |
| 5966424 |
Radiation-shielding, interpolative-sampling technique for high spatial resolution digital radiog |
October 12, 1999 |
| A method of obtaining high resolution, spatial images from a flat-panel imager is provided, in which a radiation opaque filter is provided over the flat-panel imager, interposed between the x-ray source and the patient tissue. The filter, comprised of x-ray and similar high energy radiat |
| 5962239 |
Method for detection of anti-HLA antibodies |
October 5, 1999 |
| An improved method for detecting even low titer HLA antibodies in proposed organ transplant recipients employs flow cytometry crossmatching (FCXM) on pronase-treated B-cells and T-cells of the donor. Two-color FCXM is preferably employed. The peripheral blood lymphocytes, after pronase |
| 5902787 |
Chemically modified a-macroglobulins, methods of making, and methods of using the same in anti-c |
May 11, 1999 |
| Chemically modified .alpha.-macroglobulin is conformationally locked by cross-linking .alpha..sub.2 M with a bi-functional peptide crosslinker, and then modified with methylamine, to provide conformational intermediates with limited conformational change. These modified compounds hav |
| 5895843 |
In situ sensor for critical corrosion conditions in a material |
April 20, 1999 |
| An in situ sensor for monitoring the degree of corrosion of rebar in a concrete structure relies on a four-point resistance measure of a test wire embedded in the concrete structure. The resistance across the wire is compared with the resistance of a reference wire, which is corrosion |
| 5891634 |
Transfection of enteric parasites |
April 6, 1999 |
| The invention provides methods for expressing foreign genes in enteric protozoa. This transfection system was established using a gene ligated to the 5' and 3' flanking DNA regions of a protein-encoding gene from an enteric protozoa. The present invention also provides such transformed |
| 5885791 |
Antifungal and antibacterial susceptibility assay |
March 23, 1999 |
| An assay and test kit for testing and quantifying fungal inhibition by an antifungal agent. In the assay, inhibition is measured by a reduction in substrate uptake (such as glucose) as compared to uninhibited controls. A minimum inhibitory concentration value for each antifungal agent is |
| 5869288 |
Molecular cloning of cockroach allergens, amino acid and nucleotide sequences therefore and reco |
February 9, 1999 |
| Four cockroach allergens are purified, described, characterized and sequenced. The nucleotide sequence responsible for expression of the allergen, and the amino acid sequence thereof, are set forth. These allergens induce IgE antibody binding, which may generate an allergic or asthma |
| 5852187 |
Molecular cloning of the ovine pituitary growth hormone releasing hormone receptor |
December 22, 1998 |
| Growth hormone releasing hormone (GHRH) receptor binding has been characterized using a unique binding assay utilizing iodinated GHRH probes. Photoaffinity GHRH probes have been constructed which allow for photolabeling and characterization of the receptor. In addition, high affinity |
| 5834644 |
Automatic atomic force microscope with piezotube scanner |
November 10, 1998 |
| An atomic force microscope which can provide an automatic operation of focusing a laser beam onto a cantilever of the atomic force microscope, and which can ensure that a laser beam reflected off this cantilever is properly directed to a detector. A tip supported by the cantilever can |
| 5830472 |
Purified sperm surface antigen, monoclonal antibody therefor and applications therefor |
November 3, 1998 |
| The monoclonal antibody S19, expressed by Deposit HB12144, ATCC, effectively agglutinates a sperm surface glycoprotein, SAGA-1 protein. The mAB finds utility as a binding agent in a spermicide, showing a high degree of effectiveness in binding potential sperm. The protein bound, iden |
| 5814066 |
Reduction of femoral arterial bleeding post catheterization using percutaneous application of fi |
September 29, 1998 |
| Post catheterization arterial bleeding is reduced by introduction of a fibrin sealant, prepared from fibrinogen and thrombin, into the periarterial tissue surround the arteriotomy through which the catheter was inserted. The fibrin sealant is introduced as the catheter is withdrawn, |
| 5808445 |
Method for monitoring remaining battery capacity |
September 15, 1998 |
| A complete energy management system for lead-acid batteries. The system is designed for deep discharge batteries in traction vehicle type applications such as electric wheelchairs, electric vehicles, golf carts, or industrial equipment, where more efficient use of lead-acid batteries |
| 5792215 |
Laser integrated targeting and entry system and method |
August 11, 1998 |
| A guidance system and method for accurately reproducing surgical approach angles for increasing the efficiency and accuracy of image-guided biopsy procedures which require high levels of precision with respect to the orientation of surgical instruments prior to insertion. A tri-axial |
| 5772993 |
Osteocalcin promoter-based toxic gene therapy for the treatment of calcified tumors and tissues |
June 30, 1998 |
| A recombinant adenovirus Ad-OC-TK was constructed, with cell specific gene expression, which contains osteocalcin (OC) promoter that drives the expression of herpes simplex virus thymidine kinase (TK); the addition of acyclovir (ACV), a pro-drug for the inhibition of cell proliferation, |
| 5696229 |
Polypeptide with laminin cell adhesion and morphogenesis activity |
December 9, 1997 |
| The present invention provides novel cell adhesion peptides. |
| 5665565 |
Transfection of enteric parasites |
September 9, 1997 |
| The invention provides methods for expressing foreign genes in enteric protozoa. This transfection system was established using a gene ligated to the 5' and 3' flanking DNA regions of a protein-encoding gene from an enteric protozoa. The present invention also provides such transformed |
| 5652221 |
Method of treating defective glucose metabolism using synthetic insulin substances |
July 29, 1997 |
| A synthetic insulin mimetic compound is disclosed. Small synthetic amines of disaccharides, such as 2-deoxy-2-amino-galactopyranosyl pinitol are shown to mimic the action of insulin and to modulate its action. |
| 5644046 |
Cloning of a gene encoding for the growth hormone releasing hormone receptor |
July 1, 1997 |
| Growth hormone releasing hormone (GHRH) receptor binding has been characterized using a unique binding assay utilizing iodinated GHRH probes. Photoaffinity GHRH probes have been constructed which allow for photolabeling and characterization of the receptor. In addition, high affinity |
| 5635540 |
Stabilized topical pharmaceutical preparations |
June 3, 1997 |
| The present invention relates to stabilized topical pharmaceutical preparations. More specifically the present invention relates to a stabilized topical pharmaceutical preparation, based on the solubilization of a eutectic mixture of local anesthetic agents, in base form, which when |
| 5626691 |
Bulk nanocrystalline titanium alloys with high strength |
May 6, 1997 |
| Bulk nanocrystalline Ti-based alloys were produced by conventional cooling from the corresponding liquid or high temperature solid phase followed by annealing at an appropriate temperature for a certain amount of time. The titanium-based alloys have a composition represented by the follo |
| 5612470 |
Nucleic acid encoding the growth hormone releasing hormone receptor |
March 18, 1997 |
| Growth hormone releasing hormone (GHRH) receptor binding has been characterized using a unique binding assay utilizing iodinated GHRH probes. Photoaffinity GHRH probes have been constructed which allow for photolabeling and characterization of the receptor. In addition, high affinity |
| 5591641 |
Nucleic acid encoding the growth hormone releasing hormone receptor |
January 7, 1997 |
| Growth hormone releasing hormone (GHRH) receptor binding has been characterized using a unique binding assay utilizing iodinated GHRH probes. Photoaffinity GHRH probes have been constructed which allow for photolabeling and characterization of the receptor. In addition, high affinity |
| 5583010 |
Nucleic acid molecule encoding the porcine growth hormone receptor |
December 10, 1996 |
| Growth hormone releasing hormone (GHRH) receptor binding has been characterized using a unique binding assay utilizing iodinated GHRH probes. Photoaffinity GHRH probes have been constructed which allow for photolabeling and characterization of the receptor. In addition, high affinity |
| 5561111 |
Stable glutamine derivatives for oral and intravenous rehydration and nutrition therapy |
October 1, 1996 |
| A method for the treatment of dehydration or nitrogen deficiency-based malnutrition is provided which involves administering to a patient in need thereof an effective amount of a compound selected from oligopeptides formed from the coupling of one or more amino acids with glutamine, the |
| 5525526 |
Immunoassay for inositols |
June 11, 1996 |
| Antibodies raised against derivatives of inositol are used to assay for specific isomers of inositol in a sample by first converting any inositol present in the sample to the derivative that was used to raise the antibody and then conducting an immunoassay for the inositol derivative in |
| 5493008 |
Two non-contiguous regions contribute to nidogen binding to a single EGF-like motif of the lamin |
February 20, 1996 |
| High affinity binding of nidogen to laminin is mediated by an EGF-like repeat .gamma.1III4 of the mouse laminin .gamma.1 chain and has now been restricted to two short non-contiguous regions of its 56 residue sequence by use of synthetic peptides and recombinant mutants. Disulfide loop a |
| 5436239 |
Method of treating clostridium difficile colitis and cholera |
July 25, 1995 |
| The invention relates to the treatment of antibiotic associated colitis, typically due to Clostridium difficile using the Platelet Activating Factor antagonists WEB 2170, SR 27417 or BN 52021, or the cyclooxygenase antagonist indomethacin. The PAF antagonists BN 52021 and SR 27417 and th |
| 5427956 |
Quantitative analysis for diabetic condition predictor |
June 27, 1995 |
| An enhanced quantitative assay for chiro-inositol concentration can be used to determine insulin-resistance, or a predisposition to the development of insulin-resistance, in type I and type II diabetics. Spot urine or serum samples reflecting concentrations of chiro-inositol below about |
